Category Archives: Blogs

How do different types of DTx fit into a Drug Discovery Lifecycle?


Understanding the different types of DTx Understanding Digital Therapeutics (DTx) is key to understanding both its current and potential roles in the drug discovery lifecycle. DTx utilises software solutions to prevent, manage and treat medical issues but delivering evidence-based therapeutic interventions. By using best practice and advanced technology in clinical evaluation, DTx products, once certified

The Impact of Digital Therapeutics on Patient Health


What element do you think most influences a patient’s health? Social circumstances? Genetics? Treatments? Environment? All of these have an impact of course, but by far the leading element affecting patient health is behavioural patterns . In fact, behavioural patterns account for 40% of patient health, according to The New England Journal of Medicine. [1]

Pharma Checklist for Choosing the Right DTx Partner


If you’ve decided that it’s time to explore the world of Pharma DTx relationships, then you’ll need the right partner. However, with so many different potential DTx partners out there right now, who’s the best fit for your business? Introduction Across healthcare, adoption of digital transformation and technologies has been the norm for almost two

The 6 Simple Steps to Building Great Pharma DTx Partnerships


Having partnered with numerous pharma companies around the world, we know a fair bit about building great DTx partnerships at Wellthy. But what makes a truly great partnership? How do you know what to look for in a partner? And what value does it actually drive for pharma? At Wellthy we know what it takes,

Pharma Leader, Karine Soulat joins Wellthy therapeutics as VP Marketing


Introducing Karine Soulat, VP Marketing at Wellthy Therapeutics Wellthy Therapeutics is delighted to announce the arrival of Karine Soulat, digital therapeutics and healthcare marketing expert to the senior team. Karine brings a wealth of over 25 years experience working with top ten global pharmaceutical companies Biogen and Bristol Myer-Squibb across global and for European markets.

Pulmonary Hypertension: How Wellthy’s digital tools can improve quality of life


Established by the PHA Association, Pulmonary Hypertension Awareness Month is now in its 30th year and encourages those who are connected to the condition to help spread awareness. Co-founder and VP of Partnerships Prayat Shah explains how Wellthy is working with the PH community and how our technology is improving the lives of those living

Wellthy Therapeutics complies to IEC:62304 medical device standard to build and scale robust SaMD solutions


The IEC 62304 standard outlines the life cycle processes, activities, and tasks that are required for the safe design and maintenance of medical device software.1 Adherence to the standard process ensures that necessary actions and precautions have been taken to prevent the risk of an event involving a threat to the life of a patient.

Diabetes: Connecting the Dots for Collaborative Diabetes Care

Diabetes: Connecting the dots for collaborative diabetes care

The theme for this year’s Diabetes Awareness Month is, ‘Access to Diabetes Care: If not now, when?’ urging greater access and care for people living with all types of diabetes. Prayat Shah, Wellthy co-founder and Vice President of Partnerships, explains why type 2 diabetes is an important focus for our team and the wellthy CARE™

The next stage of Pharma-DTx partnerships: what still remains unsolved?


The digital health ecosystem has grown at a tremendous pace in the last decade; not only when it comes to technological advancements, but also on patient adoption, traction from life sciences, and the global regulatory and compliance environment front. What began as a tool, limited for academia and technology research, has now shifted into being

How Digital Therapeutics can handhold Healthcare workers to achieve optimal insulin titration


Patients with diabetes may require insulin therapy at a certain point in their journey of living with diabetes. Insulin initiation is recommended when patient’s A1c is ≥7% even after 3 months of triple combination with oral anti-diabetes medicines (OAD) or if patient’s A1c levels are ≥10% (1).  The American Diabetes Association recommends that insulin initiation